Sysmex Corporation TSE:6869
Sysmex : Financial Data( PDF format / 718KB )
Source: MarketScreener
FINANCIAL DATA (IFRS)
3rd Quarter
Fiscal Year Ending March 31, 2026
[2026年3月期 第3四半期]
April 1, 2025 - December 31, 2025
⽬次 CONTENTS
連結決算概要／Financial Summary (Consolidated) 1
連結財政状態計算書／Consolidated statement of financial position 3
連結損益計算書／Consolidated statement of income 5
連結キャッシュ・フ□ー計算書／Consolidated statement of cash flows 6
地域別・事業別・品⽬別売上⾼／Net Sales by Destination,Business and Product type 8
地域別・事業別売上⾼／Net Sales by Destination and Business 9
地域別・品⽬別売上⾼／Net Sales by Destination and Product type 12
統括会社別売上⾼および営業利益の状況／Net Sales and Operating Income (Loss) by Geographical Region 13
関連データ／Associated Data 14
会社概要／Corporate Data 15
補⾜事項 Notes
2025年3⽉期第4四半期にシスメックス グリース アイケーイーをギリシャに設⽴しました。
In the first quarter of the fiscal year ended March 31st, 2026, Sysmex established Sysmex Greece I.K.E., in Greece. 2025年3⽉期第4四半期にシスメックス イーストアフリカをケニアに設⽴しました。
In the 4th quarter of the fiscal year ended March 31st, 2025, Sysmex established Sysmex East Africa Ltd., in Kenya.
2025年3⽉期第1四半期より、報告セグメントを「所在地別」から「統括会社別」へ変更しました。
From the first quarter of the fiscal year ending March 31, 2025, we have revised our reportable segments to be by managing company rather than by geographic segment. 2024年3⽉期第3四半期に株式会社メガカリオンを⼦会社化しました。
In the third quarter of the fiscal year ended March 31, 2024, Megakaryon Corporation became a subsidiary.
2023年3⽉期第2四半期にシスメックスピ□ート株式会社を⼦会社化しました。
In the second quarter of the fiscal year ended March 31, 2023, Sysmex Pilot Co., Ltd. became a subsidiary.
2022年3⽉期に、クラウド・コンピューティング契約におけるコンフィギュレーションまたはカスタマイゼーションのコストについて、サービスを受領したときにそのコストを
⽤として認 識する⽅法に変更しています。In the fiscal year ended March 31, 2022, the Sysmex Group changed its method of recognizing the costs of configuration or customization services in cloud computing contracts as an expense when these services are received. Comparisons with the fiscal year ended March 31, 2021 have been made using figures that have been retroactively adjusted for this change.
2023年3⽉期第1四半期にシスメックス アストレゴ エービーを⼦会社化しました。
In the first quarter of the fiscal year ended March 31, 2023, Sysmex Astrego AB became a subsidiary.
注意事項 Cautionary Notes
本資料のうち、業績⾒通し等に記載されている各数値は、現在⼊⼿可能な情報による判断および仮定に基づき算出しており、判断や仮定に内在する不確定性および今後の事業運営や内外の状況変化により、実際の業績等が⾒通しの数値と⼤きく異なる可能性があります。
This material contains forward-looking statements about Sysmex Corporation and its group companies (the Sysmex Group). These forward-looking statements are based on current judgments and assumptions of the Sysmex Group in light of the information currently available to it, and involve known and unknown risks, uncertainties and other factors, including but not limited to: global economic conditions, competitive situations and changes in exchange rates. Such risks, uncertainties and other factors may cause our actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by these forward-looking statements.
連結決算概要 第3四半期 Financial Summary (Consolidated)[3rd Quarter]
（百万円）（JPY million）
項⽬ Item | 決算期 Fiscal Term | 2022.3 3Q | 2023.3 3Q | 2024.3 3Q | 2025.3 3Q | 2026.3 3Q | 2026.3 通期予想 Forecast | |
売上⾼ | Net sales | 258,901 | 298,743 | 326,525 | 366,866 | 361,168 | 500,000 | |
売上原価 | Cost of sales | 121,524 | 143,877 | 154,751 | 168,056 | 173,537 | 244,000 | |
売上総利益 | Gross profit | 137,377 | 154,866 | 171,774 | 198,809 | 187,631 | 256,000 | |
販売 及び⼀般管理 | Selling, general and administrative expenses | 67,767 | 81,551 | 95,849 | 109,971 | 120,206 | 165,000 | |
研究開発 | Research and development expenses | 18,315 | 22,064 | 23,219 | 22,542 | 20,444 | 30,000 | |
その他の営業損益 | Other operating income (expenses) | △1,935 | 3,121 | 1,507 | 1,049 | 1,676 | 1,000 | |
営業利益 | Operating profit | 49,358 | 54,372 | 54,212 | 67,345 | 48,657 | 62,000 | |
四半期（当期）利益 | Profit | 32,429 | 35,104 | 34,487 | 42,497 | 33,522 | 41,000 | |
親会社の所有者に帰属する 四半期（当期）利益 | Profit attributable to owners of the parent | 32,546 | 35,185 | 34,464 | 42,615 | 33,694 | 41,000 | |
希薄化後1株当たり四半期（ 当期）利益（円） | Diluted earnings per share(￥) | 51.79 | 56.03 | 54.94 | 68.33 | 54.05 | 65.77 | |
親会社所有者帰属持分四半 期（当期）利益率 | Return on equity［ROE］ | - | - | - | - | - | 8.5 | |
売上総利益率 | Gross profit per net sales | 53.1 | 51.8 | 52.6 | 54.2 | 52.0 | 51.2 | |
売上⾼営業利益率 | Operating profit to net sales | 19.0 | 18.2 | 16.6 | 18.4 | 13.5 | 12.4 | |
売上⾼四半期（当期）利益 率 | Profit attributable to owners of the parent to net sales | 12.6 | 11.8 | 10.6 | 11.6 | 9.3 | 8.2 | |
売上⾼研究開発 率 | R&D expenditure per net sales | 7.1 | 7.4 | 7.1 | 6.1 | 5.7 | 6.0 |
項⽬ Item | 決算期 Fiscal Term | 2022.3 F.Y. | 2023.3 F.Y. | 2024.3 F.Y. | 2025.3 F.Y. | 2026.3 3Q |
資本⾦ | Capital stock | 14,112 | 14,282 | 14,729 | 14,887 | 14,898 |
⾃⼰株式控除後期末株式 数（千株） | Number of outstanding stock excluding treasury stock (thousand shares) | 627,630.3 | 627,739.5 | 623,498.7 | 623,599.8 | 623,180.0 |
資本合計 | Total equity | 349,053 | 388,356 | 432,897 | 464,534 | 501,429 |
資産合計 | Total assets | 483,707 | 531,074 | 618,920 | 665,268 | 698,249 |
親会社所有者帰属持分⽐ 率 | Equity attributable to owners of the parent to total assets | 72.0 | 73.0 | 69.8 | 69.7 | 71.7 |
１株当たり親会社所有者 帰属持分(円） | Equity attributable to owners of the parent per share（￥） | 554.94 | 617.56 | 692.94 | 743.71 | 803.69 |
決算期 Fiscal Term
項⽬ Item
営業活動によるキ ャッシュ・フ□ー投資活動によるキャッシュ・フ□ー財務活動によるキャッシュ・フ□ー
現⾦及び現⾦同等 物の期末残⾼
2022.3 3Q
2023.3 3Q
2024.3 3Q
2025.3 3Q
2026.3 3Q
Net cash provided by (used in) operating activities
Net cash provided by (used in) investment activities
Net cash provided by (used in) financing activities Cash and cash equivalents at the end of the term
50,015
△ 25,742
△ 18,869
73,445
39,881
△ 38,508
△ 22,346
55,014
38,868
△ 41,861
△ 10,707
59,362
58,922
△ 34,146
△ 22,520
81,940
50,044
△ 37,560
△ 32,705
75,760
項⽬ Item
設備投資 ※
減価償却 及 び償却
2022.3 3Q
2023.3 3Q
2024.3 3Q
2025.3 3Q
2026.3 3Q
Capital expenditure ※
Depreciation and amortization
22,402
20,776
28,149
23,552
33,890
26,165
32,381
28,700
34,614
34,820
設備投資の状況 Capital Expenditure
※有形、無形含む
※Includes both tangible and intangible assets
●通期予想は、2026年2⽉に修正したものです。
Business forecast was revised in February 2026.
2026.3 通期予想
Forecast
50,000
45,000
1
換算レート（通期実績） Average Exchange Rate (Annual)
決算期 Fiscal Term | 2022.3 F.Y. | 2023.3 F.Y. | 2024.3 F.Y. | 2025.3 F.Y. | 2026.3 通期予想 Forecast |
USドル USD （円） (JPY) | 112.4 | 135.5 | 144.6 | 152.6 | 150.1 |
ユー□ EUR （円） (JPY) | 130.6 | 141.0 | 156.8 | 163.8 | 174.6 |
元 CNY （円） (JPY) | 17.5 | 19.8 | 20.1 | 21.1 | 21.1 |
換算レート（期中平均） Average Exchange Rate (Periods)
決算期 Fiscal Term 項⽬ Item | 2022.3 3Q | 2023.3 3Q | 2024.3 3Q | 2025.3 3Q | 2026.3 3Q |
USドル USD （円） (JPY) | 111.1 | 136.5 | 143.3 | 152.6 | 148.7 |
ユー□ EUR （円） (JPY) | 130.6 | 140.6 | 155.3 | 164.8 | 171.8 |
元 CNY （円） (JPY) | 17.3 | 19.9 | 20.0 | 21.2 | 20.8 |
●通期予想は、2026年2⽉に修正したものです。
●Business forecast was revised in February 2026.
資産 Assets （百万円）（構成⽐︓%）（JPY million）(Ratio︓%)
項⽬ Item | 2022.3 F.Y. | 2023.3 F.Y. | 2024.3 F.Y. | 2025.3 F.Y. | 2026.3 3Q | 増減 (Variance) | ||||||
Ratio | Ratio | Ratio | Ratio | Ratio | ||||||||
流動資産 | Current assets | |||||||||||
現⾦及び現⾦同等物 | Cash and cash equivalents | 73,752 | 15.2 | 69,460 | 13.1 | 75,507 | 12.2 | 89,570 | 13.5 | 75,760 | 10.9 | △13,810 |
営業債権及びその他の 債権 | Trade and other receivables | 118,697 | 24.5 | 126,319 | 23.8 | 157,067 | 25.4 | 163,007 | 24.5 | 161,705 | 23.2 | △1,302 |
棚卸資産 | Inventories | 61,944 | 12.8 | 73,310 | 13.8 | 79,123 | 12.8 | 81,811 | 12.3 | 99,367 | 14.2 | 17,556 |
その他の短期⾦融資 産 | Other short-term financial assets | 1,498 | 0.3 | 875 | 0.2 | 1,310 | 0.2 | 654 | 0.1 | 637 | 0.1 | △17 |
未収法⼈所得税 | Income taxes receivable | 470 | 0.1 | 600 | 0.1 | 934 | 0.2 | 1,246 | 0.2 | 4,929 | 0.7 | 3,683 |
その他の流動資産 | Other current assets | 18,728 | 3.9 | 24,924 | 4.7 | 29,515 | 4.8 | 28,531 | 4.3 | 30,879 | 4.4 | 2,348 |
流動資産合計 | Total current assets | 275,092 | 56.9 | 295,491 | 55.6 | 343,459 | 55.5 | 364,821 | 54.8 | 373,280 | 53.5 | 8,459 |
⾮流動資産 | Non-current assets | |||||||||||
有形固定資産 | Property, plant and equipment | 98,525 | 20.4 | 102,106 | 19.2 | 116,693 | 18.9 | 130,211 | 19.6 | 144,843 | 20.7 | 14,632 |
のれん | Goodwill | 13,010 | 2.7 | 16,842 | 3.2 | 17,221 | 2.8 | 14,205 | 2.1 | 15,592 | 2.2 | 1,387 |
無形資産 | Intangible assets | 57,260 | 11.8 | 73,530 | 13.8 | 86,786 | 14.0 | 92,146 | 13.9 | 93,016 | 13.3 | 870 |
持分法で会計処理されている投資 | Investments accounted for using the equity method | 986 | 0.2 | 92 | 0.0 | 472 | 0.1 | 339 | 0.1 | 200 | 0.0 | △139 |
営業債権及びその他の 債権 | Trade and other receivables | 16,403 | 3.4 | 17,895 | 3.4 | 21,435 | 3.5 | 26,978 | 4.1 | 32,452 | 4.6 | 5,474 |
その他の⻑期⾦融資 産 | Other long-term financial assets | 9,157 | 1.9 | 9,777 | 1.8 | 14,034 | 2.3 | 12,034 | 1.8 | 15,036 | 2.2 | 3,002 |
退職給付に係る資産 | Asset for retirement benefits | 841 | 0.2 | 614 | 0.1 | 458 | 0.1 | 0 | 0.0 | 55 | 0.0 | 55 |
その他の⾮流動資産 | Other non-current assets | 3,910 | 0.8 | 3,842 | 0.7 | 4,339 | 0.7 | 6,880 | 1.0 | 6,925 | 1.0 | 45 |
繰延税⾦資産 | Deferred tax assets | 8,520 | 1.8 | 10,880 | 2.0 | 14,018 | 2.3 | 17,651 | 2.7 | 16,845 | 2.4 | △806 |
⾮流動資産合計 | Total non-current assets | 208,614 | 43.1 | 235,583 | 44.4 | 275,461 | 44.5 | 300,447 | 45.2 | 324,968 | 46.5 | 24,521 |
資産合計 | Total assets | 483,707 | 100.0 | 531,074 | 100.0 | 618,920 | 100.0 | 665,268 | 100.0 | 698,249 | 100.0 | 32,981 |
3
負債および資本 Liabilities and Equity （百万円）（構成⽐︓%）（JPY million）(Ratio︓%)
項⽬ Item | 決算期 Fiscal Term | 2022.3 F.Y. | 2023.3 F.Y. | 2024.3 F.Y. | 2025.3 F.Y. | 2026.3 3Q | 増減 (Variance) | |||||
Ratio | Ratio | Ratio | Ratio | Ratio | ||||||||
負債 | Liabilities | |||||||||||
流動負債 | Current liabilities | |||||||||||
営業債務及びその他の債 務 | Trade and other payables | 32,111 | 6.6 | 31,678 | 6.0 | 33,602 | 5.4 | 31,865 | 4.8 | 31,120 | 4.5 | △745 |
リース負債 | Lease liabilities | 6,439 | 1.3 | 7,149 | 1.3 | 8,659 | 1.4 | 9,250 | 1.4 | 9,402 | 1.3 | 152 |
その他の短期⾦融負債 | Other short-term financial liabilities | 1,482 | 0.3 | 3,537 | 0.7 | 1,028 | 0.2 | 1,403 | 0.2 | 1,372 | 0.2 | △31 |
未払法⼈所得税 | Income taxes payable | 12,813 | 2.6 | 14,662 | 2.8 | 12,476 | 2.0 | 12,784 | 1.9 | 4,193 | 0.6 | △8,591 |
引当⾦ | Provisions | 1,234 | 0.3 | 1,123 | 0.2 | 1,159 | 0.2 | 1,164 | 0.2 | 1,183 | 0.2 | 19 |
契約負債 | Contract Liabilities | 12,852 | 2.7 | 14,469 | 2.7 | 16,591 | 2.7 | 18,098 | 2.7 | 19,815 | 2.8 | 1,717 |
未払 ⽤ | Accrued expenses | 17,498 | 3.6 | 18,772 | 3.5 | 21,643 | 3.5 | 22,355 | 3.4 | 22,733 | 3.3 | 378 |
未払賞与 | Accrued bonuses | 10,985 | 2.3 | 11,360 | 2.1 | 12,611 | 2.0 | 14,709 | 2.2 | 10,192 | 1.5 | △4,517 |
その他の流動負債 | Other current liabilities | 6,663 | 1.4 | 8,348 | 1.6 | 10,311 | 1.7 | 11,194 | 1.7 | 12,186 | 1.7 | 992 |
流動負債合計 | Total current liabilities | 102,082 | 21.1 | 111,102 | 20.9 | 118,084 | 19.1 | 122,826 | 18.5 | 112,200 | 16.1 | △10,626 |
⾮流動負債 | Non-current liabilities | |||||||||||
⻑期借⼊⾦ | Long-term loans payable | - | - | - | - | 28,600 | 4.6 | 32,359 | 4.9 | 31,850 | 4.6 | △509 |
リース負債 | Lease liabilities | 15,840 | 3.3 | 15,442 | 2.9 | 18,080 | 2.9 | 23,126 | 3.5 | 29,774 | 4.3 | 6,648 |
その他の⻑期⾦融負債 | Other long-term financial liabilities | 30 | 0.0 | 305 | 0.1 | 76 | 0.0 | 56 | 0.0 | 41 | 0.0 | △15 |
退職給付に係る負債 | Liability for retirement benefits | 1,183 | 0.2 | 1,959 | 0.4 | 2,239 | 0.4 | 2,127 | 0.3 | 2,506 | 0.4 | 379 |
引当⾦ | Provisions | 366 | 0.1 | 398 | 0.1 | 674 | 0.1 | 1,054 | 0.2 | 1,286 | 0.2 | 232 |
その他の⾮流動負債 | Other non-current liabilities | 8,537 | 1.8 | 7,059 | 1.3 | 10,350 | 1.7 | 11,608 | 1.7 | 12,212 | 1.7 | 604 |
繰延税⾦負債 | Deferred tax liabilities | 6,613 | 1.4 | 6,450 | 1.2 | 7,917 | 1.3 | 7,575 | 1.1 | 6,948 | 1.0 | △627 |
⾮流動負債合計 | Total non-current liabilities | 32,571 | 6.7 | 31,615 | 6.0 | 67,938 | 11.0 | 77,908 | 11.7 | 84,619 | 12.1 | 6,711 |
負債合計 | Total Liabilities | 134,654 | 27.8 | 142,718 | 26.9 | 186,023 | 30.1 | 200,734 | 30.2 | 196,820 | 28.2 | △3,914 |
資本 | Equity | |||||||||||
親会社の所有者に帰属する持分 | Equity attributable to owners of the parent | |||||||||||
資本⾦ | Capital stock | 14,112 | 2.9 | 14,282 | 2.7 | 14,729 | 2.4 | 14,887 | 2.2 | 14,898 | 2.1 | 11 |
資本剰余⾦ | Capital surplus | 20,483 | 4.2 | 20,580 | 3.9 | 20,830 | 3.4 | 20,960 | 3.2 | 21,011 | 3.0 | 51 |
利益剰余⾦ | Retained earnings | 305,710 | 63.2 | 334,192 | 62.9 | 365,985 | 59.1 | 402,820 | 60.6 | 414,032 | 59.3 | 11,212 |
⾃⼰株式 | Treasury stock | △312 | 0.1 | △314 | 0.1 | △12,315 | 2.0 | △12,318 | 1.9 | △13,165 | 1.9 | △847 |
その他の資本の構成要 素 | Other components of equity | 8,309 | 1.7 | 18,925 | 3.6 | 42,814 | 6.9 | 37,425 | 5.6 | 64,066 | 9.2 | 26,641 |
親会社の所有者に帰属する持分合計 | Total equity attributable to owners of the parent | 348,303 | 72.0 | 387,665 | 73.0 | 432,045 | 69.8 | 463,776 | 69.7 | 500,842 | 71.7 | 37,066 |
⾮⽀配持分 | Non-controlling interests | 750 | 0.2 | 690 | 0.1 | 851 | 0.1 | 758 | 0.1 | 586 | 0.1 | △172 |
資本合計 | Total equity | 349,053 | 72.2 | 388,356 | 73.1 | 432,897 | 69.9 | 464,534 | 69.8 | 501,429 | 71.8 | 36,895 |
負債及び資本合計 | Total liabilities and equity | 483,707 | 100.0 | 531,074 | 100.0 | 618,920 | 100.0 | 665,268 | 100.0 | 698,249 | 100.0 | 32,981 |
（百万円）（構成⽐︓%）（JPY million）(Ratio︓%)
決算期 Fiscal Term | 2022.3 3Q | 2023.3 3Q | 2024.3 3Q | 2025.3 3Q | 2026.3 3Q | |||||||
項⽬ Item | Ratio | Ratio | Ratio | Ratio | Ratio | |||||||
売上⾼ | Net sales | 258,901 | 100.0 | 298,743 | 100.0 | 326,525 | 100.0 | 366,866 | 100.0 | 361,168 | 100.0 | |
売上原価 | Cost of sales | 121,524 | 46.9 | 143,877 | 48.2 | 154,751 | 47.4 | 168,056 | 45.8 | 173,537 | 48.0 | |
売上総利益 | Gross profit | 137,377 | 53.1 | 154,866 | 51.8 | 171,774 | 52.6 | 198,809 | 54.2 | 187,631 | 52.0 | |
販売 及び⼀般管理 | Selling, general and administrative expenses | 67,767 | 26.2 | 81,551 | 27.3 | 95,849 | 29.4 | 109,971 | 30.0 | 120,206 | 33.3 | |
研究開発 | Research and development expenses | 18,315 | 7.1 | 22,064 | 7.4 | 23,219 | 7.1 | 22,542 | 6.1 | 20,444 | 5.7 | |
減損損失 | Impairment loss | - | - | - | - | - | - | - | - | - | - | |
その他の営業収益 | Other operating income | 1,121 | 0.4 | 3,809 | 1.3 | 2,494 | 0.8 | 1,647 | 0.4 | 2,785 | 0.8 | |
その他の 営業 | ⽤ | Other operating expenses | 3,056 | 1.2 | 687 | 0.2 | 986 | 0.3 | 598 | 0.2 | 1,108 | 0.3 |
営業利益 | Operating profit | 49,358 | 19.0 | 54,372 | 18.2 | 54,212 | 16.6 | 67,345 | 18.4 | 48,657 | 13.5 | |
⾦融収益 | Financial income | 446 | 0.2 | 628 | 0.2 | 731 | 0.2 | 760 | 0.2 | 711 | 0.2 | |
⾦融 ⽤ | Financial expenses | 609 | 0.2 | 1,276 | 0.4 | 1,650 | 0.5 | 2,181 | 0.6 | 2,661 | 0.7 | |
持分法による投資損益 | Share of profit (loss) of associates accounted for using the equity method | △2,084 | 0.8 | △1,892 | 0.6 | △2,382 | 0.7 | △1,727 | 0.5 | △1,249 | 0.3 | |
為替差損益 | Foreign exchange gain (loss) | 442 | 0.2 | △773 | 0.3 | 190 | 0.1 | △2,404 | 0.7 | 2,013 | 0.6 | |
税引前四半期（当期）利 益 | Profit before tax | 47,554 | 18.4 | 51,058 | 17.1 | 51,102 | 15.7 | 61,792 | 16.8 | 47,471 | 13.1 | |
法⼈所得税 ⽤ | Income taxes expenses | 15,124 | 5.8 | 15,954 | 5.3 | 16,614 | 5.1 | 19,295 | 5.3 | 13,948 | 3.9 | |
四半期（当期）利益 | Profit | 32,429 | 12.5 | 35,104 | 11.8 | 34,487 | 10.6 | 42,497 | 11.6 | 33,522 | 9.3 | |
四半期（当期）利益の帰 属 | Profit attributable to | ||||||||||
親会社の所有者 | Owners of the parent | 32,546 | 12.6 | 35,185 | 11.8 | 34,464 | 10.6 | 42,615 | 11.6 | 33,694 | 9.3 |
⾮⽀配持分 | Non-controlling interests | △117 | 0.0 | △81 | 0.0 | 23 | 0.0 | △118 | 0.0 | △171 | 0.0 |
四半期（当期）利益 | Profit | 32,429 | 12.5 | 35,104 | 11.8 | 34,487 | 10.6 | 42,497 | 11.6 | 33,522 | 9.3 |
1株当たり四半期（当期） 利益 | Earnings per share | ||||||||||
基本的1株当たり四半期（ 当期）利益 | Basic | 51.89 | - | 56.06 | - | 54.97 | - | 68.35 | - | 54.05 | - |
希薄化後1株当たり四半期 （当期）利益 | Diluted | 51.79 | - | 56.03 | - | 54.94 | - | 68.33 | - | 54.05 | - |
5
連結キャッシュ・フロー計算書 Consolidated statement of cash flows
決算期 Fiscal Term
（百万円）（JPY million）
項⽬ Item
営業活動によるキャッシュ・フロー Cash flows from operating activities
税引前四半期利益 Profit before tax
減価償却 及び償却 Depreciation and amortization
減損損失 Impairment loss
受取利息及び受取配当⾦ Interest and dividends income
⽀払利息 Interest expenses
持分法による投資損益 Share of profit (loss) of associates accounted for using the equity method
固定資産等除却損 Loss on retirement of non-current assets
営業債権の増減額 Decrease (increase) in trade receivable
前渡⾦の増減額 Decrease (increase) in advance payments
棚卸資産の増減額 Decrease (increase) in inventories
営業債務の増減額 Increase (decrease) in trade payable
未払⾦の増減額 Increase (decrease) in accounts payable-other
契約負債の増減額 Increase (decrease) in contract liabilities
未払 ⽤の増減額 Increase (decrease) in accrued expense
未払⼜は未収消 税等の増減額 Incrrease(Decrease) in consumption taxes receivable and payable
未払賞与の増減額 Increase (decrease) in accrued bonuses
その他 Other
⼩計 Subtotal
利息及び配当⾦の受取額 Interest and dividend received
利息の⽀払額 Interest paid
法⼈所得税の⽀払額 Income taxes paid
営業活動によるキャッシュ・フロー Net cash provided by (used in) operating activities
2022.3 3Q
47,554
20,776
-
-
-2,084
-3,021
△306
△15,946
3,261
1,367
△1,172
-932
△2,076 2,901
62,398
222
△525
△12,080 50,015
2023.3 3Q
51,058
23,552
-
-
-1,892
-3,450
△815
△13,266
518
△2,494
313
62
1,402
△3,841
631
62,466
371
△744
△22,211 39,881
2024.3 3Q
51,102
26,165
-
-
-2,382
273
△2,537
392
△7,182
△816
△2,235
△570 2,216
1,498
△3,136
△1,850 65,700
426
△924
△26,333 38,868
2025.3 3Q
61,792
28,700
-
-
-1,727
166
9,036
458
△12,391
111
△1,721
865
681
△741
△2,479
△1,579 84,628
474
△1,285
△24,895 58,922
2026.3 3Q
47,471
34,820
-
-
-1,249
620
13,342
△1,021
△12,602
280
△1,040
511
△892 330
△4,867
△569 77,634
471
△1,603
△26,457 50,044
（百万円）（JPY million）
決算期 Fiscal Term
項⽬ Item
投資活動によるキャッシュ・フロー Cash flows from investing activities
2022.3 3Q
2023.3 3Q
2024.3 3Q
2025.3 3Q
2026.3 3Q
有形固定資産の取得による⽀出 | Purchases of property, plant and equipment | △10,179 | △11,971 | △18,590 | △17,697 | △22,191 |
有形固定資産の売却による収⼊ | Proceeds from sales of property, plant and equipment | - | - | - | - | - |
無形資産の取得による⽀ 出 | Purchases of intangible assets | △13,533 | △17,382 | △18,196 | △16,063 | △13,549 |
⻑期前払 ⽤の増加を伴 う⽀出 | Payments resulting in an increase in long-term prepaid expenses | △848 | △404 | △396 | △626 | △758 |
資本性⾦融商品の取得による⽀出 | Purchases of investments in equity instruments | - | △5,181 | △3,834 | △2,008 | △254 |
資本性⾦融商品の売却による収⼊ | Proceeds from sales of investments in equity instruments | - | - | - | 1,853 | 0 |
負債性⾦融商品の取得による⽀出 | Purchases of investments in debt instruments | - | - | △150 | △399 | △978 |
⼦会社⼜はその他の事業 の取得による⽀出 | Acquisitions of subsidiaries or other businesses | - | △2,984 | △574 | - | - |
定期預⾦の預⼊による⽀ 出 | Payments into time deposits | △553 | △519 | △1,192 | △1,306 | △977 |
定期預⾦の払戻による収 ⼊ | Proceeds from withdrawals of time deposits | 678 | 769 | 1,018 | 1,591 | 893 |
その他 | Other | △1,307 | △833 | 56 | 510 | 255 |
投資活動によるキャッシュ・フロー | Net cash provided by (used in) investing activities | △25,742 | △38,508 | △41,861 | △34,146 | △37,560 |
財務活動によるキャッシュ・フロー | Cash flows from financing activities | |||||
⻑期借⼊れによる収⼊ | Proceeds from long-term loans payable | - | - | 25,000 | 3,500 | - |
⻑期借⼊⾦の返済による⽀ 出 | Repayment of long-term loans payable | - | - | - | △435 | △508 |
株式の発⾏による収⼊ | Proceeds from Issuance of Common Stock | 1,262 | 184 | 432 | 191 | 16 |
⾃⼰株式の取得による⽀出 | Purchases of treasury stock | - | △1 | △12,000 | △2 | △877 |
配当⾦の⽀払額 | Dividends paid | △15,258 | △16,528 | △17,579 | △18,081 | △22,441 |
リース負債の返済による⽀払 額 | Repayments of lease liabilities | △4,865 | △5,989 | △6,492 | △7,692 | △8,925 |
その他 | Other | △7 | △11 | △67 | 0 | 31 |
財務活動によるキャッシュ・フロー | Net cash provided by (used in) financing activities | △18,869 | △22,346 | △10,707 | △22,520 | △32,705 |
現⾦及び現⾦同等物に係る 換算差額 | Effects of exchange rate changes on cash and cash equivalents | 1,574 | 2,235 | 3,602 | 4,177 | 6,412 |
現⾦及び現⾦同等物の純増 減額 | Net increase (decrease) in cash and cash equivalents | 6,977 | △18,738 | △10,097 | 6,432 | △13,809 |
現⾦及び現⾦同等物の期⾸ 残⾼ | Cash and cash equivalents at the beginning of the term | 66,467 | 73,752 | 69,460 | 75,507 | 89,570 |
現⾦及び現⾦同等物の期末 残⾼ | Cash and cash equivalents at the end of the term | 73,445 | 55,014 | 59,362 | 81,940 | 75,760 |
7
地域別・事業別・品⽬別売上⾼ Net Sales by Destination, Business and Product type
地域別売上⾼ Net Sales by Destination （百万円）（構成⽐・対前年⽐︓%）（JPY million）(Ratio･Y O Y︓%)
決算期 Fiscal Term 地域 Destination | 2022.3 3Q | 2023.3 3Q | 2024.3 3Q | 2025.3 3Q | 2026.3 3Q | 2026.3 通期予想 Forecast | |||||||||||
Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | |||||||
国 内 Japan | 39,283 | 15.1 | 118.0 | 43,765 | 14.6 | 111.4 | 43,315 | 13.3 | 99.0 | 47,190 | 12.9 | 108.9 | 40,509 | 11.2 | 85.8 | 58,000 | 11.6 |
⽶州 Americas | 59,275 | 22.9 | 129.9 | 77,236 | 25.9 | 130.3 | 85,310 | 26.1 | 110.5 | 96,425 | 26.3 | 113.0 | 100,829 | 27.9 | 104.6 | 139,000 | 27.8 |
EMEA※1 EMEA | 70,504 | 72.3 | 125.3 | 78,791 | 70.5 | 111.8 | 91,168 | 27.9 | 115.7 | 102,871 | 28.0 | 112.8 | 114,909 | 31.8 | 111.7 | 161,500 | 32.3 |
中国 China | 62,792 | 24.3 | 111.3 | 66,038 | 22.1 | 105.2 | 73,460 | 22.5 | 111.2 | 82,000 | 22.3 | 111.6 | 65,533 | 18.2 | 79.9 | 86,000 | 17.2 |
ｱｼﾞｱ･ﾊﾟｼﾌｨｯｸ※1 Asia-Pacific | 27,045 | 27.7 | 133.4 | 32,911 | 29.5 | 121.7 | 33,269 | 10.2 | 101.1 | 38,378 | 10.5 | 115.4 | 39,386 | 10.9 | 102.6 | 55,500 | 11.1 |
海外 計 Overseas Total | 219,618 | 84.9 | 123.0 | 254,978 | 85.4 | 116.1 | 283,210 | 86.7 | 111.1 | 319,675 | 87.1 | 112.9 | 320,659 | 88.8 | 100.3 | 442,000 | 88.4 |
合 計 Total Sales | 258,901 | 100.0 | 122.2 | 298,743 | 100.0 | 115.4 | 326,525 | 100.0 | 109.3 | 366,866 | 100.0 | 112.4 | 361,168 | 100.0 | 98.4 | 500,000 | 100.0 |
EMEA︓欧州、中東、アフリカ地域 ●EMEA: Europe, the Middle East and Africa
※1 □シアの売上はEMEAからAPへ組み替えています。
※1 Sales for Russia have been recategorized from the EMEA segment to the AP segment.
事業別売上⾼ Net Sales by Business （百万円）（構成⽐・対前年⽐︓%）（JPY million）(Ratio･Y O Y︓%)
事業 Business
決算期 Fiscal Term
2022.3 3Q
2023.3 3Q
2024.3 3Q
2025.3 3Q
2026.3 3Q
2026.3 通期予想
Forecast
Ratio
Y O Y
Ratio
Y O Y
Ratio
Y O Y
Ratio
Y O Y
Ratio
Y O Y
Ratio
⾎球計数検 査
Hematology
151,834
58.6
119.2
175,552
58.8
115.6
195,326
59.8
111.3
221,236
60.3
113.3
216,990
60.1
98.1
299,500
59.9
FCM検査
FCM
1,444
0.6
154.9
1,748
0.6
121.0
2,407
0.7
137.7
2,382
0.6
99.0
2,941
0.8
123.5
5,000
1.0
尿検査
Urinalysis
20,791
8.0
146.9
24,024
8.0
115.6
27,930
8.6
116.3
30,234
8.2
108.3
32,036
8.9
106.0
46,500
9.3
⾎液凝固検 査
Hemostasis
43,589
16.8
114.8
48,963
16.4
112.3
50,836
15.6
103.8
57,267
15.6
112.6
53,763
14.9
93.9
72,000
14.4
免疫検査
Immunochemistry
13,728
5.3
130.3
16,712
5.6
121.7
16,500
5.1
98.7
18,351
5.0
111.2
15,952
4.4
86.9
21,500
4.3
⽣化学検査
Clinical Chemistry
2,249
0.9
112.3
2,639
0.9
117.3
2,480
0.8
94.0
2,652
0.7
106.9
2,133
0.6
80.4
3,000
0.6
ライフサイエン ス
Life Science
12,567
4.9
148.2
14,946
5.0
118.9
15,119
4.6
101.2
15,904
4.3
105.2
17,000
4.7
106.9
24,500
4.9
その他
Others
11,948
4.6
114.7
12,446
4.2
104.2
13,914
4.3
111.8
15,542
4.2
111.7
18,032
5.0
116.0
24,500
4.9
ダイアグノスティ クス事業
Diagnostics Business
258,153
99.7
121.9
297,034
99.4
115.1
324,515
99.4
109.3
363,572
99.1
112.0
358,850
99.4
98.7
496,500
99.3
メディカル□ボット事業
合 計
Medical Robotics Business
Total Sales
748
258,901
0.3
100.0
11,091.4
122.2
1,709
298,743
0.6
100.0
228.5
115.4
2,010
326,525
0.6
100.0
117.6
109.3
3,294
366,866
0.9
100.0
163.9
112.4
2,317
361,168
0.6
100.0
70.3
98.4
3,500
500,000
0.7
100.0
品⽬別売上⾼ Net Sales by Product Type （百万円）（構成⽐・対前年⽐︓%）（JPY million）(Ratio･Y O Y︓%)
品⽬ Product
Type
決算期 Fiscal Term
2022.3 3Q
2023.3 3Q
2024.3 3Q
2025.3 3Q
2026.3 3Q
2026.3 通期予想
Forecast
Ratio
Y O Y
Ratio
Y O Y
Ratio
Y O Y
Ratio
Y O Y
Ratio
Y O Y
Ratio
機器
Instrument
59,113
22.8
104.5
64,433
21.6
109.0
68,665
21.0
106.6
71,218
19.4
103.7
70,520
19.5
99.0
104,000
20.8
試薬
Reagent
156,800
60.6
130.8
182,253
61.0
116.2
199,717
61.2
109.6
229,142
62.5
114.7
225,863
62.5
98.6
308,500
61.7
サービス
Service
33,259
12.8
119.1
39,972
13.4
120.2
44,790
13.7
112.1
50,589
13.8
112.9
50,978
14.1
100.8
69,500
13.9
その他
合計
Others
Total Sales
9,727
258,901
3.8
100.0
131.2
122.2
12,083
298,743
4.0
100.0
124.2
115.4
13,352
326,525
4.1
100.0
110.5
109.3
15,915
366,866
4.3
100.0
119.2
112.4
13,805
361,168
3.8
100.0
86.7
98.4
18,000
500,000
3.6
100.0
●通期予想は、2026年2⽉に修正したものです 。
Business forecast was revised in February 2026.
地域別・事業別売上⾼ Net Sales by Destination and Business
決算期 Fiscal Term
2022.3 3Q
2023.3 3Q
2024.3 3Q
2025.3 3Q
2026.3 3Q
⽇本 Japan （百万円）（構成⽐・対前年⽐︓%）（JPY million）(Ratio･Y O Y︓%)
事業 Business | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | ||||||
⾎球計数検 査 | Hematology | 14,291 | 36.4 | 102.0 | 14,828 | 33.9 | 103.8 | 15,236 | 35.2 | 102.8 | 18,273 | 38.7 | 119.9 | 14,334 | 35.4 | 78.4 |
FCM検査 | FCM | 193 | 0.5 | 506.5 | 73 | 0.2 | 38.2 | 53 | 0.1 | 73.0 | 65 | 0.1 | 120.9 | 72 | 0.2 | 111.6 |
尿検査 | Urinalysis | 2,331 | 5.9 | 111.4 | 2,355 | 5.4 | 101.0 | 2,640 | 6.1 | 112.1 | 2,188 | 4.6 | 82.9 | 2,193 | 5.4 | 100.2 |
⾎液凝固検 査 | Hemostasis | 7,476 | 19.0 | 114.0 | 7,626 | 17.4 | 102.0 | 7,910 | 18.3 | 103.7 | 8,395 | 17.8 | 106.1 | 7,481 | 18.5 | 89.1 |
免疫検査 | Immunochemistry | 5,711 | 14.5 | 150.5 | 8,284 | 18.9 | 145.0 | 6,806 | 15.7 | 82.2 | 6,810 | 14.4 | 100.1 | 5,972 | 14.7 | 87.7 |
⽣化学検査 | Clinical Chemistry | 826 | 2.1 | 97.6 | 814 | 1.9 | 98.6 | 787 | 1.8 | 96.6 | 785 | 1.7 | 99.7 | 725 | 1.8 | 92.3 |
ライフサイエン ス | Life Science | 4,452 | 11.3 | 188.4 | 4,703 | 10.7 | 105.6 | 4,289 | 9.9 | 91.2 | 3,973 | 8.4 | 92.6 | 3,607 | 8.9 | 90.8 |
その他 | Others | 3,252 | 8.3 | 90.6 | 3,371 | 7.7 | 103.7 | 3,580 | 8.3 | 106.2 | 3,440 | 7.3 | 96.1 | 3,927 | 9.7 | 114.2 |
ダイアグノスティクス事業 | Diagnostics Business | 38,535 | 98.1 | 115.8 | 42,056 | 96.1 | 109.1 | 41,304 | 95.4 | 98.2 | 43,932 | 93.1 | 106.4 | 38,314 | 94.6 | 87.2 |
メディカル□ボット事業 | Medical Robotics Business | 748 | 1.9 | 11,091.4 | 1,709 | 3.9 | 228.5 | 2,010 | 4.6 | 117.6 | 3,257 | 6.9 | 162.0 | 2,195 | 5.4 | 67.4 |
合 計 | Total Sales | 39,283 | 100.0 | 118.0 | 43,765 | 100.0 | 111.4 | 43,315 | 100.0 | 99.0 | 47,190 | 100.0 | 108.9 | 40,509 | 100.0 | 85.8 |
海外 Overseas | ||||||||||||||||
決算期 Fiscal Term 2022.3 3Q 2023.3 3Q 2024.3 3Q 2025.3 3Q 2026.3 3Q | ||||||||||||||||
事業 Business | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | ||||||
⾎球計数検 査 | Hematology | 137,543 | 62.6 | 121.3 | 160,724 | 63.0 | 116.9 | 180,089 | 63.6 | 112.0 | 202,962 | 63.5 | 112.7 | 202,656 | 63.2 | 99.8 |
FCM検査 | FCM | 1,251 | 0.6 | 139.9 | 1,674 | 0.7 | 133.8 | 2,353 | 0.8 | 140.6 | 2,317 | 0.7 | 98.5 | 2,868 | 0.9 | 123.8 |
尿検査 | Urinalysis | 18,459 | 8.4 | 153.1 | 21,669 | 8.5 | 117.4 | 25,289 | 8.9 | 116.7 | 28,046 | 8.8 | 110.9 | 29,842 | 9.3 | 106.4 |
⾎液凝固検 査 | Hemostasis | 36,113 | 16.4 | 115.0 | 41,337 | 16.2 | 114.5 | 42,925 | 15.2 | 103.8 | 48,871 | 15.3 | 113.9 | 46,282 | 14.4 | 94.7 |
免疫検査 | Immunochemistry | 8,017 | 3.7 | 118.9 | 8,428 | 3.3 | 105.1 | 9,694 | 3.4 | 115.0 | 11,541 | 3.6 | 119.1 | 9,979 | 3.1 | 86.5 |
⽣化学検査 | Clinical Chemistry | 1,423 | 0.6 | 123.1 | 1,824 | 0.7 | 128.2 | 1,693 | 0.6 | 92.8 | 1,866 | 0.6 | 110.3 | 1,408 | 0.4 | 75.4 |
ライフサイエン ス | Life Science | 8,114 | 3.7 | 132.6 | 10,243 | 4.0 | 126.2 | 10,829 | 3.8 | 105.7 | 11,930 | 3.7 | 110.2 | 13,393 | 4.2 | 112.3 |
その他 | Others | 8,696 | 4.0 | 127.4 | 9,075 | 3.6 | 104.4 | 10,333 | 3.6 | 113.9 | 12,102 | 3.8 | 117.1 | 14,105 | 4.4 | 116.5 |
ダイアグノスティクス事業 | Diagnostics Business | 219,618 | 100.0 | 123.0 | 254,978 | 100.0 | 116.1 | 283,210 | 100.0 | 111.1 | 319,639 | 100.0 | 112.9 | 320,536 | 100.0 | 100.3 |
メディカル□ボット事業 | Medical Robotics Business | - | - | - | - | - | - | - | - | - | 36 | 0.0 | - | 122 | 0.0 | - |
合 計 | Total Sales | 219,618 | 100.0 | 123.0 | 254,978 | 100.0 | 116.1 | 283,210 | 100.0 | 111.1 | 319,675 | 100.0 | 112.9 | 320,659 | 100.0 | 100.3 |
9
決算期 Fiscal Term
2022.3 3Q
2023.3 3Q
2024.3 3Q
2025.3 3Q
2026.3 3Q
⽶州 Americas （百万円）（構成⽐・対前年⽐︓%）（JPY million）(Ratio･Y O Y︓%)
事業 Business | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | ||||||
⾎球計数検 査 | Hematology | 49,553 | 83.6 | 121.9 | 63,577 | 82.3 | 128.3 | 68,505 | 80.3 | 107.8 | 76,810 | 79.7 | 112.1 | 78,527 | 77.9 | 102.2 |
FCM検査 | FCM | 356 | 0.6 | 198.4 | 429 | 0.6 | 120.2 | 857 | 1.0 | 199.8 | 804 | 0.8 | 93.8 | 678 | 0.7 | 84.4 |
尿検査 | Urinalysis | 5,756 | 9.7 | 478.6 | 8,182 | 10.6 | 142.2 | 10,809 | 12.7 | 132.1 | 12,128 | 12.6 | 112.2 | 14,011 | 13.9 | 115.5 |
⾎液凝固検 査 | Hemostasis | 1,951 | 3.3 | 83.4 | 2,136 | 2.8 | 109.4 | 1,851 | 2.2 | 86.7 | 2,040 | 2.1 | 110.2 | 2,267 | 2.2 | 111.1 |
免疫検査 | Immunochemistry | 1 | 0.0 | 97.7 | 3 | 0.0 | 217.8 | 149 | 0.2 | 4,707.7 | 756 | 0.8 | 505.5 | 938 | 0.9 | 124.1 |
⽣化学検査 | Clinical Chemistry | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ライフサイエン ス | Life Science | 1,354 | 2.3 | 112.4 | 2,333 | 3.0 | 172.4 | 2,196 | 2.6 | 94.1 | 2,619 | 2.7 | 119.3 | 2,438 | 2.4 | 93.1 |
その他 | Others | 300 | 0.5 | 454.6 | 573 | 0.7 | 190.7 | 941 | 1.1 | 164.0 | 1,264 | 1.3 | 134.3 | 1,966 | 2.0 | 155.5 |
ダイアグノスティクス事業 | Diagnostics Business | 59,275 | 100.0 | 129.9 | 77,236 | 100.0 | 130.3 | 85,310 | 100.0 | 110.5 | 96,425 | 100.0 | 113.0 | 100,829 | 100.0 | 104.6 |
メディカル□ボット事業 | Medical Robotics Business | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
合 計 | Total Sales | 59,275 | 100.0 | 129.9 | 77,236 | 100.0 | 130.3 | 85,310 | 100.0 | 110.5 | 96,425 | 100.0 | 113.0 | 100,829 | 100.0 | 104.6 |
決算期 Fiscal Term
2022.3 3Q
2023.3 3Q
2024.3 3Q
2025.3 3Q
2026.3 3Q
EMEA※1 （欧州、中東、アフリカ地域 / Europe, the Middle East and Africa）
事業 Business | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | ||||||
⾎球計数検 査 | Hematology | 45,380 | 64.4 | 121.3 | 51,126 | 64.9 | 112.7 | 60,261 | 66.1 | 117.9 | 67,754 | 65.9 | 112.4 | 73,992 | 64.4 | 109.2 |
FCM検査 | FCM | 531 | 0.8 | 111.5 | 732 | 0.9 | 137.9 | 963 | 1.1 | 131.4 | 958 | 0.9 | 99.5 | 1,487 | 1.3 | 155.2 |
尿検査 | Urinalysis | 3,545 | 5.0 | 131.5 | 4,341 | 5.5 | 122.4 | 5,053 | 5.5 | 116.4 | 5,688 | 5.5 | 112.6 | 7,344 | 6.4 | 129.1 |
⾎液凝固検 査 | Hemostasis | 6,719 | 9.5 | 138.4 | 7,153 | 9.1 | 106.5 | 8,158 | 8.9 | 114.0 | 9,768 | 9.5 | 119.7 | 10,407 | 9.1 | 106.5 |
免疫検査 | Immunochemistry | 1 | 0.0 | 44.3 | 11 | 0.0 | 930.7 | 7 | 0.0 | 69.9 | 58 | 0.1 | 750.5 | 77 | 0.1 | 132.8 |
⽣化学検査 | Clinical Chemistry | 7 | 0.0 | 49.8 | 15 | 0.0 | 209.2 | 11 | 0.0 | 72.2 | 0 | 0.0 | 0.1 | 17 | 0.0 | 154,338.4 |
ライフサイエン ス | Life Science | 6,667 | 9.5 | 142.1 | 7,791 | 9.9 | 116.9 | 8,381 | 9.2 | 107.6 | 9,210 | 9.0 | 109.9 | 10,840 | 9.4 | 117.7 |
その他 | Others | 7,652 | 10.9 | 125.6 | 7,619 | 9.7 | 99.6 | 8,331 | 9.1 | 109.4 | 9,433 | 9.2 | 113.2 | 10,741 | 9.3 | 113.9 |
ダイアグノスティクス事業 | Diagnostics Business | 70,504 | 100.0 | 125.3 | 78,791 | 100.0 | 111.8 | 91,168 | 100.0 | 115.7 | 102,871 | 100.0 | 112.8 | 114,909 | 100.0 | 111.7 |
メディカル□ボット事業 | Medical Robotics Business | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
合 計 | Total Sales | 70,504 | 100.0 | 125.3 | 78,791 | 100.0 | 111.8 | 91,168 | 100.0 | 115.7 | 102,871 | 100.0 | 112.8 | 114,909 | 100.0 | 111.7 |
※1 □シアの売上はEMEAからAPへ組み替えています。
※1 Sales for Russia have been recategorized from the EMEA segment to the AP segment.
決算期 Fiscal Term
2022.3 3Q
2023.3 3Q
2024.3 3Q
2025.3 3Q
2026.3 3Q
中国 China （百万円）（構成⽐・対前年⽐︓%）（JPY million）(Ratio･Y O Y︓%)
事業 Business | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | ||||||
⾎球計数検 査 | Hematology | 25,629 | 40.8 | 116.4 | 24,297 | 36.8 | 94.8 | 29,321 | 39.9 | 120.7 | 32,882 | 40.1 | 112.1 | 24,311 | 37.1 | 73.9 |
FCM検査 | FCM | 143 | 0.2 | 105.4 | 273 | 0.4 | 190.3 | 90 | 0.1 | 33.1 | 78 | 0.1 | 87.4 | 57 | 0.1 | 72.7 |
尿検査 | Urinalysis | 6,997 | 11.1 | 106.4 | 6,235 | 9.4 | 89.1 | 6,645 | 9.0 | 106.6 | 7,023 | 8.6 | 105.7 | 5,081 | 7.8 | 72.3 |
⾎液凝固検 査 | Hemostasis | 21,962 | 35.0 | 106.3 | 26,773 | 40.5 | 121.9 | 28,500 | 38.8 | 106.5 | 32,277 | 39.4 | 113.2 | 28,292 | 43.2 | 87.7 |
免疫検査 | Immunochemistry | 7,362 | 11.7 | 117.3 | 7,564 | 11.5 | 102.7 | 8,269 | 11.3 | 109.3 | 9,044 | 11.0 | 109.4 | 7,252 | 11.1 | 80.2 |
⽣化学検査 | Clinical Chemistry | 657 | 1.0 | 118.9 | 852 | 1.3 | 129.7 | 558 | 0.8 | 65.5 | 621 | 0.8 | 111.2 | 473 | 0.7 | 76.2 |
ライフサイエン ス | Life Science | 38 | 0.1 | 22.2 | 40 | 0.1 | 102.9 | 56 | 0.1 | 141.8 | 51 | 0.1 | 91.0 | 51 | 0.1 | 100.4 |
その他 | Others | - | - | - | 1 | 0.0 | - | 17 | 0.0 | 1,107.7 | 21 | 0.0 | 122.1 | 12 | 0.0 | 60.0 |
ダイアグノスティクス事業 | Diagnostics Business | 62,792 | 100.0 | 111.3 | 66,038 | 100.0 | 105.2 | 73,460 | 100.0 | 111.2 | 82,000 | 100.0 | 111.6 | 65,533 | 100.0 | 79.9 |
メディカル□ボット事業 | Medical Robotics Business | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
合 計 | Total Sales | 62,792 | 100.0 | 111.3 | 66,038 | 100.0 | 105.2 | 73,460 | 100.0 | 111.2 | 82,000 | 100.0 | 111.6 | 65,533 | 100.0 | 79.9 |
決算期 Fiscal Term
2022.3 3Q
2023.3 3Q
2024.3 3Q
2025.3 3Q
2026.3 3Q
アジア・パシ フィック※1
Asia-Pacific
事業 Business | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | ||||||
⾎球計数検 査 | Hematology | 16,980 | 62.8 | 127.8 | 21,723 | 66.0 | 127.9 | 22,000 | 66.1 | 101.3 | 25,514 | 66.5 | 116.0 | 25,824 | 65.6 | 101.2 |
FCM検査 | FCM | 219 | 0.8 | 215.8 | 239 | 0.7 | 109.1 | 442 | 1.3 | 185.0 | 475 | 1.2 | 107.3 | 644 | 1.6 | 135.7 |
尿検査 | Urinalysis | 2,159 | 8.0 | 136.5 | 2,909 | 8.8 | 134.7 | 2,781 | 8.4 | 95.6 | 3,205 | 8.4 | 115.2 | 3,405 | 8.6 | 106.2 |
⾎液凝固検 査 | Hemostasis | 5,479 | 20.3 | 154.3 | 5,274 | 16.0 | 96.3 | 4,415 | 13.3 | 83.7 | 4,785 | 12.5 | 108.4 | 5,313 | 13.5 | 111.0 |
免疫検査 | Immunochemistry | 651 | 2.4 | 142.0 | 849 | 2.6 | 130.3 | 1,266 | 3.8 | 149.1 | 1,682 | 4.4 | 132.8 | 1,710 | 4.3 | 101.7 |
⽣化学検査 | Clinical Chemistry | 758 | 2.8 | 128.9 | 956 | 2.9 | 126.1 | 1,123 | 3.4 | 117.5 | 1,245 | 3.2 | 110.9 | 917 | 2.3 | 73.6 |
ライフサイエン ス | Life Science | 53 | 0.2 | 117.1 | 78 | 0.2 | 145.5 | 195 | 0.6 | 249.3 | 49 | 0.1 | 25.1 | 62 | 0.2 | 128.4 |
その他 | Others | 743 | 2.7 | 111.7 | 881 | 2.7 | 118.6 | 1,043 | 3.1 | 118.5 | 1,384 | 3.6 | 132.6 | 1,384 | 3.5 | 100.0 |
ダイアグノスティクス事業 | Diagnostics Business | 27,045 | 100.0 | 133.4 | 32,911 | 100.0 | 121.7 | 33,269 | 100.0 | 101.1 | 38,341 | 99.9 | 115.2 | 39,263 | 99.7 | 102.4 |
メディカル□ボット事業 | Medical Robotics Business | - | - | - | - | - | - | - | - | - | 36 | 0.1 | - | 122 | 0.3 | 334.7 |
合 計 | Total Sales | 27,045 | 100.0 | 133.4 | 32,911 | 100.0 | 121.7 | 33,269 | 100.0 | 101.1 | 38,378 | 100.0 | 115.4 | 39,386 | 100.0 | 102.6 |
※1 □シアの売上はEMEAからAPへ組み替えています。
※1 Sales for Russia have been recategorized from the EMEA segment to the AP segment.
11
地域別・品⽬別売上⾼ Net Sales by Destination and Product type （百万円）（構成⽐・対前 年⽐︓%）（JPY million）(Ratio･Y O Y︓%)
決算期 Fiscal Term 地域 Destination/品⽬ Product Type | 2022.3 3Q | 2023.3 3Q | 2024.3 3Q | 2025.3 3Q | 2026.3 3Q | ||||||||||||
Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | ||||||||
機器 | Instrument | 6,297 | 16.0 | 113.9 | 7,089 | 16.2 | 112.6 | 7,738 | 17.9 | 109.2 | 10,321 | 21.9 | 133.4 | 6,225 | 15.4 | 60.3 | |
試薬 | Reagent | 26,558 | 67.6 | 121.1 | 29,400 | 67.2 | 110.7 | 27,774 | 64.1 | 94.5 | 28,192 | 59.7 | 101.5 | 25,675 | 63.4 | 91.1 | |
⽇本 | サービス | Service | 4,968 | 12.6 | 107.1 | 5,571 | 12.7 | 112.1 | 5,919 | 13.7 | 106.2 | 6,199 | 13.1 | 104.7 | 6,390 | 15.8 | 103.1 |
Japan | その他 | Others | 1,458 | 3.7 | 122.1 | 1,705 | 3.9 | 116.9 | 1,883 | 4.3 | 110.4 | 2,477 | 5.2 | 131.5 | 2,218 | 5.5 | 89.6 |
合計 | Total Sales | 39,283 | 100.0 | 118.0 | 43,765 | 100.0 | 111.4 | 43,315 | 100.0 | 99.0 | 47,190 | 100.0 | 108.9 | 40,509 | 100.0 | 85.8 | |
機器 | Instrument | 15,533 | 26.2 | 134.6 | 19,704 | 25.5 | 126.9 | 21,661 | 25.4 | 109.9 | 20,526 | 21.3 | 94.8 | 22,241 | 22.1 | 108.4 | |
試薬 | Reagent | 27,607 | 46.6 | 130.4 | 36,437 | 47.2 | 132.0 | 40,743 | 47.8 | 111.8 | 49,081 | 50.9 | 120.5 | 50,547 | 50.1 | 103.0 | |
⽶州 | サービス | Service | 15,393 | 26.0 | 123.8 | 19,726 | 25.5 | 128.1 | 21,528 | 25.2 | 109.1 | 24,694 | 25.6 | 114.7 | 25,906 | 25.7 | 104.9 |
Americas | その他 | Others | 740 | 1.2 | 150.7 | 1,367 | 1.8 | 184.7 | 1,376 | 1.6 | 100.7 | 2,123 | 2.2 | 154.2 | 2,133 | 2.1 | 100.5 |
合計 | Total Sales | 59,275 | 100.0 | 129.9 | 77,236 | 100.0 | 130.3 | 85,310 | 100.0 | 110.5 | 96,425 | 100.0 | 113.0 | 100,829 | 100.0 | 104.6 | |
機器 | Instrument | 18,098 | 25.7 | 109.8 | 21,303 | 27.0 | 117.7 | 22,056 | 24.2 | 103.5 | 22,519 | 21.9 | 102.1 | 26,601 | 23.1 | 118.1 | |
※1 | 試薬 | Reagent | 40,783 | 57.8 | 134.4 | 44,511 | 56.5 | 109.1 | 54,678 | 60.0 | 122.8 | 64,331 | 62.5 | 117.7 | 70,949 | 61.7 | 110.3 |
EMEA | サービス | Service | 7,629 | 10.8 | 113.4 | 8,239 | 10.5 | 108.0 | 9,940 | 10.9 | 120.6 | 11,036 | 10.7 | 111.0 | 11,852 | 10.3 | 107.4 |
その他 | Others | 3,992 | 5.7 | 148.9 | 4,737 | 6.0 | 118.6 | 4,494 | 4.9 | 94.9 | 4,983 | 4.8 | 110.9 | 5,506 | 4.8 | 110.5 | |
合計 | Total Sales | 70,504 | 100.0 | 125.3 | 78,791 | 100.0 | 111.8 | 91,168 | 100.0 | 115.7 | 102,871 | 100.0 | 112.8 | 114,909 | 100.0 | 111.7 | |
機器 | Instrument | 13,180 | 21.0 | 73.3 | 9,670 | 14.6 | 73.4 | 9,907 | 13.5 | 102.5 | 9,658 | 11.8 | 97.5 | 7,963 | 12.2 | 82.4 | |
試薬 | Reagent | 43,105 | 68.6 | 130.8 | 48,452 | 73.4 | 112.4 | 54,360 | 74.0 | 112.2 | 61,627 | 75.2 | 113.4 | 50,811 | 77.5 | 82.4 | |
中国 | サービス | Service | 3,931 | 6.3 | 127.2 | 4,765 | 7.2 | 121.2 | 4,877 | 6.6 | 102.4 | 5,694 | 6.9 | 116.7 | 4,211 | 6.4 | 74.0 |
China | その他 | Others | 2,575 | 4.1 | 109.3 | 3,149 | 4.8 | 122.3 | 4,315 | 5.9 | 137.0 | 5,020 | 6.1 | 116.3 | 2,548 | 3.9 | 50.8 |
合計 | Total Sales | 62,792 | 100.0 | 111.3 | 66,038 | 100.0 | 105.2 | 73,460 | 100.0 | 111.2 | 82,000 | 100.0 | 111.6 | 65,533 | 100.0 | 79.9 | |
ｱｼﾞｱ･※1 ﾊﾟｼﾌｨｯｸ Asia- Pacific | 機器 | Instrument | 6,004 | 22.2 | 119.4 | 6,666 | 20.3 | 111.0 | 7,301 | 21.9 | 109.5 | 8,192 | 21.3 | 112.2 | 7,489 | 19.0 | 91.4 |
試薬 | Reagent | 18,745 | 69.3 | 138.7 | 23,451 | 71.3 | 125.1 | 22,161 | 66.6 | 94.5 | 25,910 | 67.5 | 116.9 | 27,880 | 70.8 | 107.6 | |
サービス | Service | 1,336 | 4.9 | 129.0 | 1,670 | 5.1 | 125.0 | 2,524 | 7.6 | 151.1 | 2,963 | 7.7 | 117.4 | 2,617 | 6.6 | 88.3 | |
その他 | Others | 960 | 3.6 | 138.8 | 1,123 | 3.4 | 116.9 | 1,282 | 3.9 | 114.2 | 1,311 | 3.4 | 102.2 | 1,398 | 3.6 | 106.6 | |
合計 | Total Sales | 27,045 | 100.0 | 133.4 | 32,911 | 100.0 | 121.7 | 33,269 | 100.0 | 101.1 | 38,378 | 100.0 | 115.4 | 39,386 | 100.0 | 102.6 | |
機器 | Instrument | 59,113 | 22.8 | 104.5 | 64,433 | 21.6 | 109.0 | 68,665 | 21.0 | 106.6 | 71,218 | 19.4 | 103.7 | 70,520 | 19.5 | 99.0 | |
試薬 | Reagent | 156,800 | 60.6 | 130.8 | 182,253 | 61.0 | 116.2 | 199,717 | 61.2 | 109.6 | 229,142 | 62.5 | 114.7 | 225,863 | 62.5 | 98.6 | |
計 | サービス | Service | 33,259 | 12.8 | 119.1 | 39,972 | 13.4 | 120.2 | 44,790 | 13.7 | 112.1 | 50,589 | 13.8 | 112.9 | 50,978 | 14.1 | 100.8 |
Total | その他 | Others | 9,727 | 3.8 | 131.2 | 12,083 | 4.0 | 124.2 | 13,352 | 4.1 | 110.5 | 15,915 | 4.3 | 119.2 | 13,805 | 3.8 | 86.7 |
合計 | Total Sales | 258,901 | 100.0 | 122.2 | 298,743 | 100.0 | 115.4 | 326,525 | 100.0 | 109.3 | 366,866 | 100.0 | 112.4 | 361,168 | 100.0 | 98.4 | |
EMEA︓欧州、中東、アフリカ地域 ●EMEA: Europe, the Middle East and Africa
※1 □シアの売上はEMEAからAPへ組み替えています。
※1 Sales for Russia have been recategorized from the EMEA segment to the AP segment.
（百万円）（構成⽐・対前年⽐︓%）（JPY million）(Ratio･Y O Y︓%)
統括会社 Managing
company
決算期 Fiscal Term
2022.3 3Q
2023.3 3Q
2024.3 3Q
2025.3 3Q
2026.3 3Q
Ratio
Y O Y
Ratio
Y O Y
Ratio
Y O Y
Ratio
Y O Y
Ratio
Y O Y
本社統括
Headquarters
外部売 上⾼
Sales to Customers
52,293
37.1
116.0
58,009
36.3
110.9
60,046
36.1
103.5
66,472
36.7
110.7
60,580
39.1
91.1
内部売 上⾼
Intra-area Transfer
88,779
62.9
120.5
101,756
63.7
114.6
106,159
63.9
104.3
114,446
63.3
107.8
94,204
60.9
82.3
売上⾼ 計
Total Sales
141,072
100.0
118.8
159,766
100.0
113.3
166,206
100.0
104.0
180,918
100.0
108.9
154,785
100.0
85.6
営業利益
Operating Income
27,191
19.3
124.9
37,204
23.3
136.8
35,447
21.3
95.3
42,445
23.5
119.7
19,043
12.3
44.9
⽶州統括
Americas RHQ
外部売 上⾼
Sales to Customers
55,494
100.0
131.8
72,950
99.9
131.5
80,469
100.0
110.3
90,553
100.0
112.5
95,061
100.0
105.0
内部売 上⾼
Intra-area Transfer
16
0.0
267.5
38
0.1
237.1
28
0.0
74.2
18
0.0
65.7
20
0.0
110.5
売上⾼ 計
Total Sales
55,510
100.0
131.8
72,989
100.0
131.5
80,497
100.0
110.3
90,572
100.0
112.5
95,082
100.0
105.0
営業利益
Operating Income
3,658
6.6
250.4
3,582
4.9
97.9
5,569
6.9
155.4
5,405
6.0
97.1
6,289
6.6
116.4
※1
EMEA統括 EMEA RHQ
外部売 上⾼
Sales to Customers
68,255
94.5
125.8
76,922
95.3
112.7
88,994
99.1
115.7
99,408
99.5
111.7
111,082
99.6
111.7
内部売 上⾼
Intra-area Transfer
3,975
5.5
132.8
3,754
4.7
94.4
786
0.9
20.9
463
0.5
58.9
467
0.4
101.0
売上⾼ 計
Total Sales
72,230
100.0
126.2
80,677
100.0
111.7
89,780
100.0
111.3
99,872
100.0
111.2
111,550
100.0
111.7
営業利益
Operating Income
11,112
15.4
160.3
9,540
11.8
85.9
7,785
8.7
81.6
7,807
7.8
100.3
8,864
7.9
113.5
中国統括
China RHQ
外部売 上⾼
Sales to Customers
62,738
100.0
111.4
65,965
100.0
105.1
73,341
99.5
111.2
81,897
99.5
111.7
65,414
99.6
79.9
内部売 上⾼
Intra-area Transfer
21
0.0
5,322.6
30
0.0
140.3
348
0.5
1,134.6
427
0.5
122.8
271
0.4
63.5
売上⾼ 計
Total Sales
62,760
100.0
111.4
65,996
100.0
105.2
73,690
100.0
111.7
82,325
100.0
111.7
65,686
100.0
79.8
営業利益
Operating Income
7,389
11.8
242.1
6,761
10.2
91.5
6,396
8.7
94.6
8,234
10.0
128.7
7,467
11.4
90.7
※1
AP統括
AP RHQ
外部売 上⾼
Sales to Customers
20,120
99.9
142.8
24,894
99.8
123.7
23,673
99.8
95.1
28,534
99.9
120.5
29,027
99.9
101.7
内部売 上⾼
Intra-area Transfer
20
0.1
79.3
57
0.2
282.7
42
0.2
74.0
32
0.1
77.2
40
0.1
124.4
売上⾼ 計
Total Sales
20,141
100.0
142.7
24,952
100.0
123.9
23,716
100.0
95.0
28,567
100.0
120.5
29,068
100.0
101.8
営業利益
Operating Income
3,210
15.9
200.6
3,725
14.9
116.1
3,865
16.3
103.8
5,569
19.5
144.1
4,649
16.0
83.5
計
Total
外部売 上⾼
Sales to Customers
258,901
73.6
122.2
298,743
73.9
115.4
326,525
75.3
109.3
366,866
76.1
112.4
361,168
79.2
98.4
内部売 上⾼
Intra-area Transfer
92,813
26.4
121.0
105,637
26.1
113.8
107,364
24.7
101.6
115,389
23.9
107.5
95,005
20.8
82.3
売上⾼ 計
Total Sales
351,715
100.0
121.9
404,381
100.0
115.0
433,890
100.0
107.3
482,255
100.0
111.1
456,173
100.0
94.6
営業利益
Operating Income
52,561
14.9
151.0
60,814
15.0
115.7
59,063
13.6
97.1
69,462
14.4
117.6
46,314
10.2
66.7
消去/全社
Eliminations/
Corporate
外部売 上⾼
Sales to Customers
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
内部売 上⾼
Intra-area Transfer
△92,813
-
-
△105,637
-
-
△107,364
-
-
△115,389
-
-
△95,005
-
-
売上⾼ 計
Total Sales
△92,813
-
-
△105,637
-
-
△107,364
-
-
△115,389
-
-
△95,005
-
-
営業利益
Operating Income
△3,202
-
-
△6,441
-
-
△4,850
-
-
△2,116
-
-
2,342
-
-
連結
Consolidated
外部売 上⾼
Sales to Customers
258,901
100.0
122.2
298,743
100.0
115.4
326,525
100.0
109.3
366,866
100.0
112.4
361,168
100.0
98.4
内部売 上⾼
Intra-area Transfer
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
売上⾼ 計
Total Sales
258,901
100.0
122.2
298,743
100.0
115.4
326,525
100.0
109.3
366,866
100.0
112.4
361,168
100.0
98.4
営業利益
Operating Income
49,358
19.1
137.5
54,372
18.2
110.2
54,212
16.6
99.7
67,345
18.4
124.2
48,657
13.5
72.3
EMEA︓欧州、中東、アフリカ地域 ●EMEA: Europe, the Middle East and Africa
※1 □シアの売上、利益はEMEA統括からAP統括へ組み替えています。
※1 Sales and profits for Russia have been recategorized from the EMEA segment to the AP segment.
13
関連データ Associated Data
株式情報 Stock Information
株価推移 Stock Price Range of Sysmex Corporation 株式の所有者別状況 Composition of Shareholders by Category
※1
(円) (JPY) 18,000
16,000
14,000
12,000
10,000
8,000
6,000
4,000
2,000
0
'15/12 '16/6 '16/12 '17/6 '17/12 '18/6 '18/12 '19/6 '19/12 '20/6 '20/12 '21/6 '21/12 '22/6 '22/12 '23/6 '23/12 '24/6 '24/12 '25/6 '25/12
※1. 2024年4⽉1⽇付︓株式分割（1:3） ※ Three-for-one stock split conducted on April 1, 2024
⾦融機関
Financial Institutions
⾦融商品取引 業者
Financial Instruments Firm
その他国 内法⼈ Other Japanese Companies
外国法⼈等
Foreign Investors
個⼈、その他
Individuals and Others
（） 株式数
Number of shares
<>保有者数
Number of shereholders
16.66%
(104,901,070)
<42,328>
39.38%
(247,897,439)
<940>
20.97%
(131,982,922)
<51>
1.31%
(8,239,787)
<52>
21.68%
(136,458,858)
<360>
(2025年12⽉31⽇現在) (As of December 31, 2025)
出来⾼ Trading Volume of Sysmex Corporation 株主数の推移 発⾏済株式数 の推移
(万株) (10 thousand shares)
Number of Shareholders
(名)
Number of Shares Issued
(千株)
9000
8000
7000
6000
(Shareholders)
19,916
20,553
16,847
14,643
43,731
(thousand shares)
629,473 629,480
※1
629,371
※1
629,079
628,971
5000
4000
3000
2000
1000
0
'15/12 '16/6 '16/12 '17/6 '17/12 '18/6 '18/12 '19/6 '19/12 '20/6 '20/12 '21/6 '21/12 '22/6 '22/12 '23/6 '23/12 '24/6 '24/12 '25/6 '25/12
'22.3 '23.3 '24.3 '25.3 '25.12
'22.3 '23.3 '24.3 '25.3 '25.12
※1. 2024年4⽉1⽇付︓株式分割（1:3）
※ Three-for-one stock split conducted on April 1, 2024
シスメックス株式会社
Sysmex Corporation
本社所在地 〒651-0073 兵庫県神⼾市中央区脇浜海岸通1丁⽬5番1号
Address of Head Office 1-5-1, Wakinohama-Kaigandori, Chuo-ku,Kobe, Hyogo 651-0073, Japan
電話番号／Telephone (078)265-0500（代表）
FAX／Facsimile (078)265-0524
設⽴年⽉⽇／Date of Establishment 1968年2⽉20⽇／February 20,1968
資本⾦（千円）／Paid-in Capital (JPY thousand) 14,898,512
従業員数 ※嘱託及びパートタイマーなどを含む／Number of Employees ※Including part-time employee
単独（名）／Non-Consolidated 3,514
連結（名）／Consolidated 11,702
従業員平均年齢（才）／average age 42.1
従業員平均勤続年数（年）／average years of employment 12.5
発⾏済株式総数（千株）／Number of Shares Issued(thousand shares) 629,480
決算期／Settlement Day 3⽉31⽇／March 31
上場市場／Stock Listings 東京証券取引所 プライム市場／Tokyo Stock Exchange, Prime Market
証券コード／Stock Exchange Code Number 6869
主な事業内容 臨床検査機器、検査⽤試薬ならびに関連ソフトウェアなどの開発・製造 ・販売・輸出⼊
Main Line of Business Development,manufacture, sales, import and export of diagnostics testing instruments and reagents, and related software
主な販売先 国⽴病院、⼀般病院、⼤学、研究所、その他医療機関
Customers National and public hospitals, general hospitals, and other medical institutions, universities, and research institutes
(2025年12⽉31⽇現在) (As of December 31, 2025)
15
1-5-1 Wakinohama-Kaigandori, Chuo-ku, Kobe 651-0073, Japan
Tel. +81 (78) 265-0500 Fax. +81 (78) 265-0524
Printed in Japan